Invitae Corp. (NVTA)

24.22
NYSE : Health Services
Prev Close 24.78
Day Low/High 24.04 / 24.96
52 Wk Low/High 7.73 / 26.77
Avg Volume 1.74M
Exchange NYSE
Shares Outstanding 93.70M
Market Cap 2.32B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Short Interest In Invitae Corp Decreases By 19%

Short Interest In Invitae Corp Decreases By 19%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 508,305 share decrease in total short interest for Invitae Corp , to 2,180,478, a decrease of 18.90% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Invitae Enters Oversold Territory (NVTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Shark Bites: Traders Could Trip on This Market Bounce

Shark Bites: Traders Could Trip on This Market Bounce

V-shaped moves are more common than they used to be.

Noteworthy Thursday Option Activity: NVTA, GOGO, NUS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Invitae Corp , where a total volume of 1,213 contracts has been traded thus far today, a contract volume which is representative of approximately 121,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 52.3% of NVTA's average daily trading volume over the past month, of 232,110 shares.

NVTA: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/31/2017 settlement date, and Invitae Corp is one of the most shorted stocks of the Russell 3000, based on 7.79 "days to cover" versus the median component at 5.13. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

5 Earnings Short-Squeeze Plays

5 Earnings Short-Squeeze Plays

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.

Short Interest Increases 27% For NVTA

Short Interest Increases 27% For NVTA

The most recent short interest data has been released for the 12/15/2016 settlement date, which shows a 318,790 share increase in total short interest for Invitae Corp , to 1,498,786, an increase of 27.02% since 11/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Invitae Sees Increase In Utilization Of Its Inherited Prostate Cancer Genetic Tests

Invitae Sees Increase In Utilization Of Its Inherited Prostate Cancer Genetic Tests

Invitae Corporation (NYSE:NVTA), one of the fastest growing genetic information companies, has seen a significant increase in genetic testing for prostate cancer since the publication of landmark data showing...

Invitae Inviting as Undervalued Growth Play

Invitae Inviting as Undervalued Growth Play

The rapidly growing genetic testing concern is executing its growth plan marvelously.

Invitae And TME Research Announce Landmark New Study To Evaluate Universal Genetic Testing Of Breast Cancer Patients

Invitae And TME Research Announce Landmark New Study To Evaluate Universal Genetic Testing Of Breast Cancer Patients

Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the benefits of universal genetic testing of...

Invitae Adds Two Genes, Offers Faster Turnaround Time For Its Breast Cancer STAT Panel

Invitae Adds Two Genes, Offers Faster Turnaround Time For Its Breast Cancer STAT Panel

Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the expansion of its Breast Cancer STAT Panel with the addition of two important breast cancer predisposition genes - ATM and CHEK2...

Invitae To Present At The Canaccord Genuity Medical Technology & Diagnostics Forum

Invitae To Present At The Canaccord Genuity Medical Technology & Diagnostics Forum

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company's management team will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on...

Invitae Announces Pricing Of Public Offering Of Common Stock

Invitae Announces Pricing Of Public Offering Of Common Stock

Invitae Corporation (NYSE:NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.

Invitae Announces Proposed Public Offering Of Common Stock

Invitae Announces Proposed Public Offering Of Common Stock

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $40 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering...

(Graphic: Invitae Corporation)

(Graphic: Invitae Corporation)

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the third quarter ended September 30, 2016.

Invitae To Announce Third Quarter 2016 Financial Results And Host Conference Call On November 7, 2016

Invitae To Announce Third Quarter 2016 Financial Results And Host Conference Call On November 7, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016 and will host a conference call that day at...

Invitae Announces Multiple Scientific Presentations And Posters To Be Presented At The American Society Of Human Genetics 2016 Annual Meeting

Invitae Announces Multiple Scientific Presentations And Posters To Be Presented At The American Society Of Human Genetics 2016 Annual Meeting

This week Invitae Corporation (NYSE: NVTA), a genetic information company, is presenting multiple abstracts at the American Society of Human Genetics (ASHG) 2016 Annual Meeting in Vancouver, covering an array of...

Invitae Announces Collaboration With Helix To Build Applications For Health And Wellness

Invitae Announces Collaboration With Helix To Build Applications For Health And Wellness

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced a collaboration with Helix, a personal genomics company, to build novel, clinician-approved genetic testing applications designed to...

Invitae Announces Final Medicare Pricing Set At $925 For Hereditary Breast Cancer-Related Disorders Under New Billing Process

Invitae Announces Final Medicare Pricing Set At $925 For Hereditary Breast Cancer-Related Disorders Under New Billing Process

Invitae Corporation (NYSE: NVTA), a genetic information company, announced that the Centers for Medicare and Medicaid Services (CMS) announced final pricing for genetic testing for hereditary breast...

Genetic Counselors Recognized By Patients, Peers For Excellence In Patient Care

Genetic Counselors Recognized By Patients, Peers For Excellence In Patient Care

At the National Society of Genetic Counselors (NSGC) Annual Education Conference in Seattle, Allison Goetsch, MS, CGC, genetic counselor at Ann & Robert H.

Invitae Presenting Research On Genetic Test Panels, Increasing Access To Genetic Counseling At The National Society Of Genetic Counselors 35th Annual Education Conference

Invitae Presenting Research On Genetic Test Panels, Increasing Access To Genetic Counseling At The National Society Of Genetic Counselors 35th Annual Education Conference

This week Invitae Corporation (NYSE: NVTA), a genetic information company, is participating in the National Society of Genetic Counselors (NSGC) 35th Annual Education Conference in Seattle, highlighting new research...

5 Stocks Under $10 That Could Make You a Lot of Money

5 Stocks Under $10 That Could Make You a Lot of Money

These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GPI, HMG, SGU Downgrades: NVTA, ORCL, VALU Initiations: S Read on to get TheStreet Quant Ratings' detailed report:

Invitae Announces Major Expansion Of Its Neurology And Cardiology Test Offerings

Invitae Announces Major Expansion Of Its Neurology And Cardiology Test Offerings

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its neurology and cardiology test offering, adding 11 new panels for heritable diseases.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVG, CIT, CRNT, CX, EGL, FOE, GOOD, ISNS, KRNT, KTEC, LBY, LPX, MIXT, MPC, MTSI, NATR, NVTA, REGN, SSTK Downgrades: CBPX, DVA, FCFP, ITG, PBH, STN Initiations: CFMS, JCAP, LILA, LILAK, NIHD, PYPL Read on to get TheStreet Quant Ratings' detailed report:

Invitae Announces Second Quarter 2016 Financial Results, Secures Contract With A National Payer And Expands Its Network Of Regional Private Payers

Invitae Announces Second Quarter 2016 Financial Results, Secures Contract With A National Payer And Expands Its Network Of Regional Private Payers

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the second quarter ended June 30, 2016.

Invitae To Present At The Canaccord Genuity 36th Annual Growth Conference

Invitae To Present At The Canaccord Genuity 36th Annual Growth Conference

Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that members of the company's management team will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August...

Invitae To Announce Second Quarter 2016 Financial Results And Host Conference Call On August 8, 2016

Invitae To Announce Second Quarter 2016 Financial Results And Host Conference Call On August 8, 2016

Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it will report its second quarter 2016 financial results on Monday, August 8, 2016 and will host a conference call that day at...

Invitae Introduces New Breast Cancer STAT Panel For Patients With Breast Cancer Who Need Rapid Test Results To Guide Surgical Decisions

Invitae Introduces New Breast Cancer STAT Panel For Patients With Breast Cancer Who Need Rapid Test Results To Guide Surgical Decisions

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic testing designed for breast cancer patients whose...

TheStreet Quant Rating: D (Sell)